Curaleaf UK Becomes First British Maker of Medical Cannabis Suppositories

The British medical cannabis sector hit a manufacturing milestone this week. Curaleaf Laboratories, the UK arm of multinational cannabis operator Curaleaf, has announced that it is the first licensed manufacturer in the United Kingdom to develop and produce medical cannabis suppositories and pessaries under Good Manufacturing Practice (GMP) certification. The products are now available on prescription from clinicians listed on the UK Specialist Register and represent the country's first homegrown specialty cannabis dosage forms — a meaningful step beyond the imported flower and oils that have dominated British prescriptions since legalization in 2018.

What's Actually Different About This Launch

Up to now, virtually every medical cannabis product prescribed in the UK has been an imported finished good — primarily flower from licensed European or Israeli producers, or full-extract oils repackaged for sublingual use. Curaleaf's new line shifts production into the country itself and into a delivery format that didn't previously exist on the British market. Suppositories (rectal) and pessaries (vaginal) bypass the digestive system entirely, allowing cannabinoids to absorb through mucosal tissue directly into systemic or local circulation.

That route matters clinically for several reasons:

• Patients who cannot use oral or inhaled delivery — those with severe nausea, swallowing difficulties, gastrointestinal disease, or post-surgical contraindications — gain a route they didn't have before.
• Local pelvic pain conditions — endometriosis, vulvodynia, pelvic floor dysfunction — can be treated with localized delivery to the affected area, potentially achieving therapeutic effect at lower systemic dose.
• Onset and bioavailability profiles differ from oral cannabinoids, which makes them useful for clinicians titrating patients with complex symptom patterns.

The products are formulated to UK regulatory standards and produced under GMP guidelines — the same quality framework applied to conventional pharmaceuticals — which gives prescribers a level of consistency that imported and compounded products historically have not.

The Specialist Register Bottleneck

Britain's medical cannabis system runs through a tightly controlled prescriber network: the General Medical Council's Specialist Register. Only doctors on this register, in specific specialties, can legally prescribe unlicensed cannabis-based products for medicinal use. As of 2026, roughly 30,000 patients access medical cannabis through this pathway, the vast majority of them through private clinics rather than the National Health Service.

Curaleaf's new suppositories and pessaries route through this same gate. Specialist prescribers can write prescriptions, which then route to Curaleaf's UK pharmacy network for dispensing. The company has explicitly framed the launch as a response to clinician requests, suggesting the products were developed in dialogue with the prescribing community rather than as a speculative product expansion.

The bottleneck remains the limited number of specialists trained and willing to prescribe. The UK's cannabis market has grown steadily but slowly, constrained by both the regulatory architecture and persistent NHS reluctance to fund prescriptions outside narrow indications like severe epilepsy and chemotherapy-induced nausea.

Why It Matters for the Wider Industry

For the global cannabis sector, the Curaleaf UK announcement reads three ways:

First, it validates a maturity thesis. Mature pharmaceutical markets evolve from a single primary dosage form (flower, in cannabis's case) toward specialty formulations that target specific patient needs. The UK is now stepping onto that ladder, joining Germany — where domestic cannabis manufacturing has expanded rapidly under European GMP — as the second-largest specialty-focused European medical market.

Second, it positions Curaleaf strategically in Europe. The same company has a fast-growing German subsidiary, a cluster of UK clinics, and ongoing manufacturing investment in Portugal and Israel. Specialty formulations are higher-margin than commodity flower, and being first to market with suppositories in the UK locks in clinician relationships that competitors will need to displace.

Third, it foreshadows what U.S. operators may do post-rescheduling. If cannabis moves to Schedule III in the U.S. and pharmaceutical-style development becomes economically viable, the same playbook — GMP manufacturing, specialty dosage forms, prescriber-channel sales — becomes attractive to multistate operators. Several U.S. MSOs have already begun GMP-style buildouts in anticipation, and growth markets like Brazil are demonstrating the international demand for specialty medical formats.

The Specific Conditions Doctors Are Targeting

Suppositories and pessaries are particularly useful for conditions where targeted local action helps:

• Endometriosis pain and pelvic inflammation — pessary delivery can place CBD- or balanced-cannabinoid formulations directly into pelvic tissue.
• Hemorrhoids and rectal pain — suppositories deliver anti-inflammatory cannabinoids to the affected area.
• Severe inflammatory bowel disease (IBD) — rectal cannabinoid delivery has been studied for ulcerative colitis localized to the rectum and sigmoid colon.
• Refractory cancer pain — for patients who cannot tolerate oral or inhaled cannabis, suppositories provide a tolerable systemic route.
• Chemotherapy-induced nausea and vomiting — delivers active cannabinoids without requiring oral intake.

Curaleaf has not disclosed the specific cannabinoid profiles in the launch line, but the products will be available in CBD-dominant, balanced THC:CBD, and THC-dominant formats based on prescriber selection, in line with UK regulatory norms for medical cannabis.

What to Watch Next

The most useful indicator over the next 6–12 months will be prescription volume through the specialist register — both for suppositories specifically and for the UK medical market overall. If the new format expands access to patient populations who couldn't previously use medical cannabis, total prescription growth could accelerate. If volumes stay flat, the format will be a niche addition rather than a market expansion.

Other companies will respond. Releaf, Alternaleaf, Mamedica, and a handful of smaller UK clinic operators all source from competing manufacturers, and at least two — including a Canadian-owned producer with a UK GMP facility — are reportedly developing their own suppository programs. Expect a second entrant within 6 months and a more competitive specialty-formulation market by year-end 2026.

Key Takeaways

• Curaleaf Laboratories is the first UK manufacturer of medical cannabis suppositories and pessaries.
• Products are GMP-certified, available by prescription through clinicians on the UK Specialist Register.
• Suppositories/pessaries serve patients who cannot use oral or inhaled cannabis and enable localized pelvic pain treatment.
• The launch signals UK market maturation toward specialty formulations and tracks Germany's path.
• Expect competitive entrants and broader specialty-product growth across UK medical cannabis through 2026.

UK readers can access these formulations through the Specialist Register; U.S. readers can find a dispensary near you on Budpedia — every listing is license-checked, with menus, hours, and reviews to help you compare.